Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included p...

Full description

Bibliographic Details
Main Authors: Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-07-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296221110568

Internet

https://doi.org/10.1177/10760296221110568

Similar Items